GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 receptor agonist. High-profile endorsements, including from Elon Musk, have ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

In short, semaglutide can help people with diabetes improve their blood sugar and lose weight. Higher doses seem to work ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and ...

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.